![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: OLFML3 |
Gene summary for OLFML3 |
![]() |
Gene information | Species | Human | Gene symbol | OLFML3 | Gene ID | 56944 |
Gene name | olfactomedin like 3 | |
Gene Alias | HNOEL-iso | |
Cytomap | 1p13.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NRN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56944 | OLFML3 | AEH-subject1 | Human | Endometrium | AEH | 2.97e-36 | -6.14e-01 | -0.3059 |
56944 | OLFML3 | AEH-subject2 | Human | Endometrium | AEH | 3.35e-31 | -6.00e-01 | -0.2525 |
56944 | OLFML3 | AEH-subject3 | Human | Endometrium | AEH | 1.50e-18 | -4.71e-01 | -0.2576 |
56944 | OLFML3 | AEH-subject4 | Human | Endometrium | AEH | 5.81e-21 | -5.56e-01 | -0.2657 |
56944 | OLFML3 | AEH-subject5 | Human | Endometrium | AEH | 7.20e-37 | -6.19e-01 | -0.2953 |
56944 | OLFML3 | EEC-subject1 | Human | Endometrium | EEC | 6.85e-28 | -5.77e-01 | -0.2682 |
56944 | OLFML3 | EEC-subject2 | Human | Endometrium | EEC | 7.62e-40 | -6.21e-01 | -0.2607 |
56944 | OLFML3 | EEC-subject3 | Human | Endometrium | EEC | 3.56e-40 | -6.08e-01 | -0.2525 |
56944 | OLFML3 | EEC-subject4 | Human | Endometrium | EEC | 1.97e-27 | -5.72e-01 | -0.2571 |
56944 | OLFML3 | EEC-subject5 | Human | Endometrium | EEC | 3.93e-32 | -5.96e-01 | -0.249 |
56944 | OLFML3 | GSM5276934 | Human | Endometrium | EEC | 1.07e-05 | -3.20e-01 | -0.0913 |
56944 | OLFML3 | GSM5276935 | Human | Endometrium | EEC | 1.23e-35 | -6.18e-01 | -0.123 |
56944 | OLFML3 | GSM5276937 | Human | Endometrium | EEC | 6.88e-12 | -4.47e-01 | -0.0897 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.51e-33 | -6.37e-01 | -0.1869 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.55e-30 | -6.37e-01 | -0.1875 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.14e-29 | -6.15e-01 | -0.1883 |
56944 | OLFML3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.38e-36 | -6.01e-01 | -0.1934 |
56944 | OLFML3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.36e-43 | -6.37e-01 | -0.1917 |
56944 | OLFML3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.68e-44 | -6.37e-01 | -0.1916 |
56944 | OLFML3 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 5.24e-13 | -4.78e-01 | -0.1269 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OLFML3 | SNV | Missense_Mutation | novel | c.1021A>T | p.Ser341Cys | p.S341C | Q9NRN5 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-05-4398-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
OLFML3 | SNV | Missense_Mutation | c.1016C>A | p.Pro339His | p.P339H | Q9NRN5 | protein_coding | tolerated(0.52) | possibly_damaging(0.888) | TCGA-64-1679-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
OLFML3 | SNV | Missense_Mutation | novel | c.823G>T | p.Asp275Tyr | p.D275Y | Q9NRN5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-86-7701-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD |
OLFML3 | SNV | Missense_Mutation | novel | c.337N>A | p.Val113Met | p.V113M | Q9NRN5 | protein_coding | tolerated(0.06) | benign(0.102) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
OLFML3 | SNV | Missense_Mutation | c.1069C>T | p.Pro357Ser | p.P357S | Q9NRN5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-70-6722-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
OLFML3 | SNV | Missense_Mutation | novel | c.1122C>A | p.Ser374Arg | p.S374R | Q9NRN5 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-CV-6943-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
OLFML3 | SNV | Missense_Mutation | novel | c.623T>C | p.Val208Ala | p.V208A | Q9NRN5 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
OLFML3 | SNV | Missense_Mutation | novel | c.906N>G | p.Asp302Glu | p.D302E | Q9NRN5 | protein_coding | tolerated(0.08) | benign(0.334) | TCGA-YL-A8SL-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 8 | Hormone Therapy | casodex | CR |
OLFML3 | insertion | Frame_Shift_Ins | rs753594963 | c.795dupC | p.Tyr266LeufsTer14 | p.Y266Lfs*14 | Q9NRN5 | protein_coding | TCGA-HJ-7597-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |